Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
NBIX Neurocrine Biosciences, Inc. monthly Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E46.97 EPS (ttm)2.11 Insider Own1.00% Shs Outstand93.00M Perf Week2.48%
Market Cap8.99B Forward P/E20.07 EPS next Y4.93 Insider Trans-17.94% Shs Float90.04M Perf Month2.87%
Income204.80M PEG- EPS next Q0.26 Inst Own99.05% Short Float5.71% Perf Quarter-17.81%
Sales1.01B P/S8.94 EPS this Y74.70% Inst Trans5.21% Short Ratio6.62 Perf Half Y3.48%
Book/sh8.94 P/B11.06 EPS next Y104.14% ROA15.30% Target Price139.62 Perf Year1.25%
Cash/sh10.43 P/C9.48 EPS next 5Y- ROE29.90% 52W Range72.14 - 136.26 Perf YTD-7.97%
Dividend- P/FCF26.06 EPS past 5Y19.90% ROI6.00% 52W High-27.41% Beta1.15
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin99.10% 52W Low37.12% ATR2.97
Employees700 Current Ratio2.00 Sales Q/Q64.70% Oper. Margin27.30% RSI (14)44.08 Volatility2.85% 2.90%
OptionableYes Debt/Eq0.50 EPS Q/Q49.60% Profit Margin20.40% Rel Volume0.84 Prev Close98.54
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout0.00% Avg Volume776.06K Price98.92
Recom2.00 SMA20-0.78% SMA50-4.69% SMA200-7.72% Volume655,362 Change0.39%
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Oct-19-20 07:56AM  
New Strong Sell Stocks for October 19th
Zacks
Oct-15-20 10:45AM  
Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt?
Simply Wall St.
Oct-08-20 08:00AM  
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
GlobeNewswire
Oct-07-20 06:45AM  
Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week by Launching Monumental Moments, an Online Community Platform and Charitable Initiative to Support, Inspire and Connect People During the Pandemic
PR Newswire
Oct-06-20 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
PR Newswire
Sep-30-20 09:35AM  
Benzinga's Top Upgrades, Downgrades For September 30, 2020
Benzinga
Sep-28-20 04:01PM  
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting
PR Newswire
Sep-14-20 01:24PM  
Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug
Motley Fool +5.62%
08:43AM  
Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
PR Newswire
08:30AM  
Neurocrine launches Parkinson's therapy as COVID-19 related disruptions ease
Reuters
Sep-11-20 03:27PM  
Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy
Motley Fool
11:36AM  
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinsons Disease
GlobeNewswire
11:34AM  
Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020
PR Newswire
11:32AM  
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease
PR Newswire
Sep-09-20 09:48PM  
Neurocrine Biosciences (NBIX): Hedge Funds In Wait-and-See Mode
Insider Monkey
03:12PM  
Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Enjoyed An Impressive 102% Share Price Gain
Simply Wall St.
Sep-08-20 04:01PM  
Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
PR Newswire
Sep-03-20 04:06PM  
Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings
PR Newswire
Sep-02-20 04:01PM  
Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
PR Newswire
Aug-28-20 10:11AM  
Looking Into Neurocrine Biosciences's Return On Capital Employed
Benzinga
Aug-04-20 09:30AM  
Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
Motley Fool
08:38AM  
How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers?
Simply Wall St.
06:34AM  
How Neurocrine Biosciences Crushed It in Q2
Motley Fool
Aug-03-20 05:15PM  
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Zacks
04:37PM  
Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
Investor's Business Daily
04:01PM  
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
PR Newswire
Jul-30-20 04:01PM  
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
PR Newswire
Jul-27-20 12:31PM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jul-13-20 07:16PM  
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
Insider Monkey
04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
PR Newswire
Jul-01-20 07:00AM  
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
Reuters
Jun-25-20 12:17PM  
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
Zacks
Jun-17-20 04:04PM  
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com
Jun-16-20 07:00AM  
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
Business Wire
Jun-15-20 04:01PM  
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
PR Newswire
Jun-08-20 11:01AM  
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
PR Newswire
Jun-05-20 11:26AM  
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
Investor's Business Daily
Jun-04-20 04:01PM  
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
PR Newswire
Jun-03-20 01:44AM  
Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-01-20 11:46AM  
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
Zacks
May-29-20 04:13PM  
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
PR Newswire
May-26-20 04:01PM  
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
09:39AM  
Are Investors Undervaluing Neurocrine Biosciences, Inc. (NASDAQ:NBIX) By 33%?
Simply Wall St.
May-23-20 08:00AM  
Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely
Investor's Business Daily
May-18-20 12:16PM  
Neurocrine Biosciences Soars Into Buy Zone
Investor's Business Daily Video +6.79%
May-14-20 07:29PM  
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
PR Newswire
06:27AM  
Is Now a Good Time To Buy Neurocrine Biosciences?
Motley Fool
May-13-20 04:01PM  
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
PR Newswire
02:58PM  
The Top 10 Stocks of the Past Decade
Kiplinger
02:38PM  
IBD 50 Stocks To Watch: Top Biotech Scores Price-Target Hikes As It Nears Buy Point
Investor's Business Daily
May-12-20 04:55PM  
This IBD Stock Of The Day Is Setting Up After A Bullish First-Quarter Report
Investor's Business Daily
May-11-20 04:01PM  
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
PR Newswire
May-07-20 08:09PM  
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
Motley Fool +5.28%
05:30PM  
Neurocrine Biosciences Inc (NBIX) Q1 2020 Earnings Call Transcript
Motley Fool
04:01PM  
Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders
PR Newswire
May-06-20 05:35PM  
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
PR Newswire
May-05-20 04:01PM  
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020
PR Newswire
08:35AM  
Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season?
Zacks
Apr-29-20 12:34PM  
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Zacks
Apr-27-20 11:07AM  
Neurocrine Biosciences Parkinson's Drug Cleared by FDA
TheStreet.com
10:24AM  
Neurocrine's stock is up on FDA approval of Parkinson's drug
MarketWatch
07:39AM  
U.S. FDA approves Neurocrine's Parkinson's therapy
Reuters
07:30AM  
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
PR Newswire
Apr-24-20 11:41AM  
7 Beautiful Biotech Stocks to Buy Here
InvestorPlace
Apr-20-20 01:31PM  
Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Simply Wall St.
Apr-15-20 04:01PM  
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
PR Newswire
Apr-03-20 08:30AM  
Neurocrine Biosciences Provides COVID-19 Business Update
PR Newswire
Mar-30-20 06:06PM  
FDA Decisions on 5 Drugs Expected in 2nd Quarter
GuruFocus.com
Mar-27-20 12:45PM  
A Trio of Stocks Growing Capex Fast
GuruFocus.com
Mar-26-20 11:40AM  
COLL or NBIX: Which Is the Better Value Stock Right Now?
Zacks
Mar-18-20 02:29PM  
Top Biotech Stocks for Q2 2020
Investopedia -5.65%
Mar-14-20 10:59AM  
Should Neurocrine Biosciences (NASDAQ:NBIX) Be Disappointed With Their 97% Profit?
Simply Wall St.
Mar-11-20 08:53PM  
Hedge Funds Arent Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Insider Monkey -6.87%
02:45PM  
Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength
Investor's Business Daily
Mar-10-20 11:40AM  
COLL or NBIX: Which Is the Better Value Stock Right Now?
Zacks
Mar-05-20 02:38PM  
Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans
Investor's Business Daily
Feb-25-20 04:01PM  
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
PR Newswire
Feb-19-20 12:08PM  
Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club
Investor's Business Daily
Feb-15-20 07:37AM  
Edited Transcript of NBIX earnings conference call or presentation 4-Feb-20 9:30pm GMT
Thomson Reuters StreetEvents
Feb-07-20 09:28AM  
Earnings Miss: Neurocrine Biosciences, Inc. Missed EPS By 52% And Analysts Are Revising Their Forecasts
Simply Wall St.
Feb-05-20 09:35AM  
Can Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Improve Its Returns?
Simply Wall St.
Feb-04-20 05:55PM  
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
Zacks
04:01PM  
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
PR Newswire
07:51AM  
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
Benzinga
Feb-03-20 05:00PM  
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
PR Newswire
08:33AM  
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
Zacks
Feb-02-20 01:04PM  
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Benzinga
Jan-31-20 09:15AM  
Late Rally Lifts Stocks Despite Coronavirus Concerns
Zacks
07:48AM  
5 Top Stocks Set to Beat Earnings Estimates Next Week
Zacks
07:16AM  
Bet on Earnings Beat With 5 Top-Ranked Stocks
Zacks
Jan-28-20 12:31PM  
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
Jan-20-20 04:30PM  
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
PR Newswire
10:02AM  
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
Zacks
Jan-17-20 08:22AM  
Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
Zacks
Jan-13-20 08:30AM  
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
GlobeNewswire -8.37%
Jan-12-20 06:30PM  
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
PR Newswire
Jan-10-20 11:40AM  
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Zacks
01:00AM  
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
PR Newswire
Jan-09-20 12:10PM  
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
Zacks
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL A Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cooke JulieChief Human Resources OfficerOct 02Sale95.2698794,0229,549Oct 06 04:05 PM
ROBERTS EIRYChief Medical OfficerAug 05Sale118.842,257268,22511,446Aug 07 07:51 PM
Lloyd-Smith MalcolmChief Regulatory OfficerAug 05Sale118.862,257268,27726,971Aug 07 07:47 PM
Lippoldt DarinChief Legal OfficerAug 05Sale118.872,257268,29728,051Aug 07 07:40 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 05Sale118.832,257268,20079,593Aug 07 07:36 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 05Sale118.913,390403,101438,021Aug 07 07:29 PM
Gano KyleChief Business Development OffAug 05Sale118.872,257268,28695,997Aug 07 07:24 PM
Cooke JulieChief Human Resources OfficerAug 05Sale118.912,257268,3838,661Aug 07 07:21 PM
Bozigian Haig P.Chief Development OfficerAug 05Sale118.892,257268,324150,663Aug 07 07:14 PM
BENEVICH ERICChief Commercial OfficerAug 05Sale118.852,257268,25415,374Aug 07 06:35 PM
ABERNETHY MATTChief Financial OfficerAug 05Sale118.902,257268,3567,983Aug 07 06:22 PM
Lippoldt DarinChief Legal OfficerJul 09Option Exercise35.991,65759,63527,678Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJul 09Sale136.021,657225,38626,021Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJun 23Option Exercise32.995,000164,95031,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Option Exercise77.815,000389,05014,416Jun 25 04:19 PM
ROBERTS EIRYChief Medical OfficerJun 23Sale130.005,000650,0009,416Jun 25 04:19 PM
Lippoldt DarinChief Legal OfficerJun 23Sale130.005,000650,00026,021Jun 25 04:15 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 11Option Exercise35.905,571199,97677,563Jun 15 05:31 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Sale126.5542,7495,409,93371,992May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise32.995,000164,95031,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Sale119.9810,0001,199,800104,741May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Sale120.005,000600,00026,021May 20 07:15 PM
Bozigian Haig P.Chief Development OfficerMay 12Option Exercise63.1061,5553,884,054167,204May 14 08:09 PM
Bozigian Haig P.Chief Development OfficerMay 12Sale114.9461,5557,075,396148,633May 14 08:09 PM
ABERNETHY MATTChief Financial OfficerMay 07Option Exercise73.6015,0001,104,00020,953May 11 08:17 PM
ABERNETHY MATTChief Financial OfficerMay 07Sale110.2115,0001,653,1345,953May 11 08:17 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 07Sale105.448,682915,454104,741May 11 08:06 PM
SHERWIN STEPHEN ADirectorApr 28Sale99.3917,6871,757,96629,861Apr 30 04:27 PM
ABERNETHY MATTChief Financial OfficerApr 28Sale102.491,741178,4355,953Apr 30 04:25 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 24Sale99.452,906289,016434,971Apr 28 08:41 PM
Gano KyleChief Business Development OffApr 24Sale99.471,934192,37793,967Apr 28 08:40 PM
Cooke JulieChief Human Resources OfficerApr 24Sale99.461,934192,3646,631Apr 28 08:38 PM
Bozigian Haig P.Chief Development OfficerApr 24Sale99.461,934192,351148,633Apr 28 08:35 PM
BENEVICH ERICChief Commercial OfficerApr 24Sale99.451,934192,33813,344Apr 28 08:33 PM
ABERNETHY MATTChief Financial OfficerApr 24Sale99.521,934192,4677,694Apr 28 08:32 PM
ROBERTS EIRYChief Medical OfficerApr 24Sale99.471,934192,3769,416Apr 28 08:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 24Sale99.451,934192,32924,941Apr 28 08:44 PM
Lippoldt DarinChief Legal OfficerApr 24Sale99.491,934192,41626,021Apr 28 08:43 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 24Sale99.411,934192,258113,423Apr 28 08:42 PM
BENEVICH ERICChief Commercial OfficerApr 15Sale94.658,632817,01811,603Apr 17 09:48 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise59.6628,9691,728,14739,127Feb 11 07:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale104.5628,9693,029,08623,200Feb 11 07:21 PM
ROBERTS EIRYChief Medical OfficerFeb 07Sale103.311,623167,6757,452Feb 11 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale103.281,015104,82723,200Feb 11 07:21 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale103.321,522157,24724,124Feb 11 07:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 07Sale103.311,218125,833111,682Feb 11 07:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 07Sale103.353,248335,696432,357Feb 11 07:14 PM
Gano KyleChief Business Development OffFeb 07Sale103.331,623167,71091,975Feb 11 07:13 PM
Cooke JulieChief Human Resources OfficerFeb 07Sale103.2691394,2764,643Feb 11 07:10 PM
Bozigian Haig P.Chief Development OfficerFeb 07Sale103.331,623167,702146,641Feb 11 07:09 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale103.322,030209,74720,087Feb 11 07:08 PM
ABERNETHY MATTChief Financial OfficerFeb 07Sale103.352,030209,8075,701Feb 11 07:06 PM
Gano KyleChief Business Development OffFeb 06Sale101.411,000101,41390,514Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale101.4480381,456110,587Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale101.521,490151,25822,287Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale101.471,198121,55622,755Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale101.564,343441,068429,436Feb 07 06:44 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale101.561,395141,670145,180Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale101.481,395141,56118,262Feb 07 06:35 PM
Gano KyleChief Business Development OffFeb 05Sale103.053,690380,26287,204Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale103.151,618166,894109,320Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale103.051,948200,73320,455Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale102.981,750180,20721,133Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale103.095,449561,726423,351Feb 07 06:44 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale103.1760562,4173,821Feb 07 06:38 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale103.022,046210,779143,292Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale103.031,954201,31116,279Feb 07 06:35 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.112,632292,4455,991Jan 10 04:10 PM
ABERNETHY MATTChief Financial OfficerDec 02Sale116.331,645191,3603,876Dec 04 06:06 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Option Exercise35.995,000179,950113,408Nov 19 05:37 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Sale115.985,000579,900108,408Nov 19 05:37 PM
Lippoldt DarinChief Legal OfficerNov 08Option Exercise32.9910,000329,90026,728Nov 13 04:36 PM
LYONS GARY ADirectorNov 08Sale110.005,000550,000225,697Nov 13 04:41 PM
Lippoldt DarinChief Legal OfficerNov 08Sale110.0110,0001,100,05720,103Nov 13 04:36 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Option Exercise32.9910,188336,102118,596Nov 05 04:37 PM
LYONS GARY ADirectorNov 01Sale100.225,000501,104230,697Nov 05 04:38 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Sale100.3410,1881,022,298108,408Nov 05 04:37 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.